Cue Biopharma Announces Publication in The Journal of Clinical Investigation Highlighting Immuno-STAT Biologics for the Treatment of Chronic Infectious Diseases
October 21, 2021 at 12:00 pm EDT
Share
Cue Biopharma, Inc. announced the publication of a research study titled ?T-Cell Receptor-specific Immunotherapeutics Drive Selective In vivo HIV and CMV- specific T-Cell Expansion in Humanized Mice? in the peer-reviewed Journal of Clinical Investigation. The article extends the application of Cue Biopharma?s Immuno-STAT (Selective Targeting and Alteration of T cells) platform, also known as synTacs?, from cancer therapy to the treatment of chronic infectious diseases caused by viruses such as HIV and CMV. The study was co-authored by Steven C. Almo, Ph.D., co-founder of Cue Biopharma, professor and chair of biochemistry, professor of physiology & biophysics and the Wollowick Family Foundation chair in multiple sclerosis and immunology at Albert Einstein College of Medicine, and Harris Goldstein, M.D., director of the Einstein-Rockefeller-CUNY Center for AIDS Research, professor of pediatrics and microbiology & immunology, the Charles Michael chair in autoimmune diseases and associate dean for scientific resources, also at Albert Einstein College of Medicine.
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a novel class of injectable biologics designed to selectively engage and modulate tumor-specific T cells within the body to treat a broad range of cancers, chronic infectious diseases, and autoimmune diseases. The Companyâs proprietary Immuno-STAT (Selective Targeting and Alteration of T Cells) platform harnesses the patientâs intrinsic immune repertoire to fully exploit its potential to fight cancer and restore health while avoiding the deleterious side effects of broad immune activation. The Companyâs lead product candidate from the CUE-100 series, CUE-101, is a fusion protein biologic designed to target and activate antigen-specific T cells to fight HPV-driven cancers. Its second drug product candidate, CUE-102, targets Wilmsâ Tumor 1 protein (WT-1), an oncofetal antigen. It is also developing CUE-103 and its Neo-STAT and RDI-STAT programs outside of oncology.
Cue Biopharma Announces Publication in The Journal of Clinical Investigation Highlighting Immuno-STAT Biologics for the Treatment of Chronic Infectious Diseases